Bart Bergstein

Founded in 2013, with extensive medical experience, Ventinova Medical is a company that develops and markets innovative products for patient ventilation and airway management. We believe in creating a new ventilation concept through revolutionary products. Products that are more than just upgrades of current standard practice. With our knowledge and access to state-of-the-art technology we are able to develop ideas and solutions that surprise the medical field. The philosophy behind all our products is active expiration or expiration by suction. Ventinova's revolutionairy ventilation method, FCV®, is implemented using the Evone® mechanical ventilator in combination with a small lumen endotracheal tube: Tritube®. FCV is unique in that patient flow is fully controlled during both expiration and inspiration. This eliminates the large, sudden, flow and pressure changes in the lungs which are associated with conventional ventilation techniques. More information on our website https://www.ventinovamedical.com. You can also call us via 0031407516020 or send us an e-mail: info@ventinova.nl.

Cellnovo is an innovative medical technology company specialising in diabetes. The company develops and markets The Cellnovo System, the world's first mobile, connected, all-in-one diabetes management system that helps make life easier for people with type 1 diabetes. Compact, intuitive and entirely connected, Cellnovo’s micro-pump for insulin delivery communicates wirelessly with a locked-down Android phone, offering the quality and responsiveness that is to be expected from consumer-grade smartphones, while preserving the high-level of security of a medical-grade device. This unique device allows optimal management of diabetes whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real time. The current version of the system has received CE Mark approval and is reimbursed and available in 10 countries: France, the United Kingdom, The Netherlands, Italy, Spain, Australia, New Zealand, Israel, Greece and Cyprus. Cellnovo has a clearly-defined expansion strategy that involves accelerating the product’s commercialisation, initially in Europe and then in the United States and Asia, and increasing its production capacity to respond to a high level of demand. For more information, visit www.cellnovo.com.

AM-Pharma BV is a biopharmaceutical company developing recombinant Alkaline Phosphatase for clinical use.

Founded in 2013, with extensive medical experience, Ventinova Medical is a company that develops and markets innovative products for patient ventilation and airway management. We believe in creating a new ventilation concept through revolutionary products. Products that are more than just upgrades of current standard practice. With our knowledge and access to state-of-the-art technology we are able to develop ideas and solutions that surprise the medical field. The philosophy behind all our products is active expiration or expiration by suction. Ventinova's revolutionairy ventilation method, FCV®, is implemented using the Evone® mechanical ventilator in combination with a small lumen endotracheal tube: Tritube®. FCV is unique in that patient flow is fully controlled during both expiration and inspiration. This eliminates the large, sudden, flow and pressure changes in the lungs which are associated with conventional ventilation techniques. More information on our website https://www.ventinovamedical.com. You can also call us via 0031407516020 or send us an e-mail: info@ventinova.nl.

CEVEC is a leading provider of high-performance cell technology for the manufacturing of advanced bio-therapeutics from R&D to manufacturing scale. The company’s product portfolio comprises platform technologies for gene therapy viral vectors (AAV, Adenoviral vectors, Lentiviral vectors,), vaccines and complex recombinant proteins. With the ELEVECTA® Technology, CEVEC offers a unique solution for large-scale production of AAV vectors using producer cell lines with all necessary components stably integrated into the cell. The technology is based on suspension cells and does not require any expensive transfection reagents and cGMP plasmids. CEVEC’s CAP® Technology based on human suspension cells is the ideal production platform for RCA-free Adenoviral vectors, Lentiviral vectors, Oncolytic viruses, Viral vaccines and exosomes. With the CAP-Go® Technology CEVEC provides a solution to the increasing need for recombinant production of complex and highly glycosylated protein molecules, including laminins, coagulation factors and plasma proteins.